Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 31, 2015 1:52 AM ET

Biotechnology

Company Overview of Genta Incorporated

Company Overview

Genta Incorporated, a biopharmaceutical company, engages in the identification, development, and commercialization of novel drugs for the treatment of cancer and related diseases. Its products include Tesetaxel, a novel taxane compound that has completed Phase 2 trials in patients with advanced gastric cancer, breast cancer, bladder cancer, prostate cancer, and melanoma. The company is also developing G4544a, an orally bioavailable gallium-containing compound, which has completed a single-dose Phase 1 clinical study for the treatment of diseases associated with accelerated bone loss. In addition, it markets Ganite, an intravenous formulation of gallium nitrate to treat cancer-related hyperca...

200 Connell Drive

Berkeley Heights, NJ 07922

United States

Founded in 1988

21 Employees

Phone:

908-286-9800

Fax:

908-464-1701

Key Executives for Genta Incorporated

Genta Incorporated does not have any Key Executives recorded.

Genta Incorporated Key Developments

SEC Orders Hearings On Registration Suspension Or Revocation Against Genta Incorporated For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Genta Incorporated for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

Similar Private Companies By Industry

Company Name Region
Cell Habitats, Inc. United States
iPierian, Inc. United States
Bio-Life Labs Inc. United States
Virobay Inc. United States
Padlock Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Genta Incorporated, please visit www.genta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.